Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations

Pancreatology

Volumn 5, Issue 1, 2005, Pages 67-74

  Tseng, Jennifer F ^a   Willett, Christopher G ^a   Fernandez del Castillo, Carlos ^a   Ryan, David P ^a   Clark, Jeffrey W ^a   Zhu, Andrew X ^a   Rattner, David W ^a   Winkelmann, Jennifer L ^a   Warshaw, Andrew L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Clinical trial; Immunity; Immunotherapy; Pancreatic adenocarcinoma; Vaccines

Indexed keywords

FLUOROURACIL; GEMCITABINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MALE; PANCREAS ADENOCARCINOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; VACCINATION;

EID: 18744397574     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000084492     Document Type: Article

References (42)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Warshaw AL, Fernandez-del Castillo C: Pancreatic carcinoma. N Engl J Med 1992;326:455-465.
3. Dranoff G: Cancer gene therapy: Connecting basic research with clinical inquiry. J Clin Oncol 1998;16:2548-2556.
4. Mulligan RC: The basic science of gene therapy. Science 1993;260:926-932.
5. Tseng JF, Mulligan RC: Gene therapy in pancreatic cancer. Surg Oncol Clin North Am 2002;11:537-569.
6. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM, Ohashi PS: Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy. J Exp Med 1997;186:645-653.
7. Clary BM, Coveney EC, Blazer DG 3rd, Philip R, Lyerly HK: Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines. Surgery 1996;120:174-181.
8. von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C, Henne-Bruns D, Kremer B, Kalthoff H: Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 2001;7:925s-932s.
9. Plate JM, Harris JE: Immune cell functions in pancreatic cancer. Crit Rev Immunol 2000;20:375-392.
10. Wenger FA, Jacobi CA, Zieren J, Docke W, Volk HD, Muller JM: Tumor size and lymph-node status in pancreatic carcinoma - Is there a correlation to the preoperative immune function? Langenbecks Arch Surg 1999;384:473-478.
11. Jaffee EM, Abrams R, Cameron J, Donehower R, Duerr M, Gossett J, Greten TF, Grochow L, Hruban R, Kern S, Lillemoe KD, O'Reilly S, Pardoll D, Pitt HA, Sauter P, Weber C, Yeo C: A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum Gene Ther 1998;9:1951-1971.
12. Molrine DC, Siber GR, Samra Y, Shevy DS, MacDonald K, Cieri R, Ambrosino DM: Normal IgG and impaired IgM responses to polysaccharide vaccines in asplenic patients. J Infect Dis 1999;179:513-517.
13. Vance E, George S, Guinan EC, Wheeler C, Antin JH, Ambrosino DM, Molrine DC: Comparison of multiple immunization schedules for Haemophilus influenzas type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Bone Marrow Transplant 1998;22:735-741.
14. Battafarano DF, Battafarano NJ, Larsen L, Dyer PD, Older SA, Muehlbauer S, Hoyt A, Lima J, Goodman D, Lieberman M, Enzenauer RJ: Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998;41:1828-1834.
15. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W (eds): Current Protocols in Immunology. New York, Wiley & Sons, 1996.
16. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Dranoff G, et al: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998;95:13141-13146.
17. Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen LK, Finn CC, Clift SM, Hauda KM, Beck LA, Leiferman KM, Owens AH Jr, Piantadosi S, Dranoff G, Mulligan RC, Pardoll DM, Marshall FF: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997;57:1537-1546.
18. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG: Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999;59:5160-5168.
19. Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG Jr, Pinedo HM: Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial. Lancet 1999;353:345-350.
20. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-554.
21. Kahn S, Yamamoto F, Almoguera C, Winter E, Forrester K, Jordano J, Perucho M: The c-K-ras gene and human cancer. Anticancer Res 1987;7:639-652.
22. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC, Lillemoe KD, O'Reilly S, Abrams RA, Pardoll DM, Cameron JL, Yeo CJ: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-156.
23. Goggins M, Kern SE, Offerhaus JA, Hruban RH: Progress in cancer genetics: Lessons from pancreatic cancer. Ann Oncol 1999;10:4-8.
24. Van Laethem JL, Resibois A, Rickaert F, Deviere J, Gelin M, Cremer M, Robberecht P: Different expression of transforming growth factor beta 1 in pancreatic ductal adenocarcinoma and cystic neoplasms. Pancreas 1997;15:41-47.
25. Sunamura M, Sun L, Lozonschi L, Duda DG, Kodama T, Matsumoto G, Shimamura H, Takeda K, Kobari M, Hamada H, Matsuno S: The antiangiogenesis effect of interleukin 12 during early growth of human pancreatic cancer in SCID mice. Pancreas 2000;20:227-233.
26. Rentenaar RJ, de Metz J, Bunders M, Wertheim-van Dillen PM, Gouma DJ, Romijn JA, Sauerwein HP, ten Berge IJ, van Lier RA: Interferon-gamma administration after abdominal surgery rescues antigen-specific helper T cell immune reactivity. Clin Exp Immunol 2001;125:401-408.
27. Mukherjee P, Ginardi AR, Madsen CS, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, Gendler SJ: MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconj J 2001;18:931-942.
28. Mukherjee P, Ginardi AR, Madsen CS, Sterner CJ, Adriance MC, Tevethia MJ, Gendler SJ: Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred. J Immunol 2000;165:3451-3460.
29. Hersh EM, Gutterman JU, Mavligit GM, Mountain CW, McBride CM, Brugess MA, Lurie PM, Zelen M, Takita H, Vincent RG: Immunocompetence, immunodeficiency and prognosis in cancer. Ann NY Acad Sci 1976;276:386-406.
30. Galant SP, Flod N, Shimizu I, Granger GA, Groncy CE: Relationship between cutaneous delayed hypersensitivity and cell-mediated immunity in vitro responses assessed by diphtheria and tetanus toxoids. J Allergy Clin Immunol 1977;60:247-253.
31. Frazer IH, Collins EJ, Fox JS, Jones B, Oliphant RC, Mackay IR: Assessment of delayed-type hypersensitivity in man: A comparison of the "Multitest" and conventional intradermal injection of six antigens. Clin Immunol Immunopathol 1985;35:182-190.
32. Sega E, Mottolese M, Cordiali-Fei P, Citro G, Colizza S, Alcione A, Di Paola M: Specific and aspecific immune responsiveness in lung cancer patients: Cutaneous delayed hypersensitivity reactions to a lung cancer-associated antigen. J Surg Oncol 1980;14:315-325.
33. Christou NV, Tellado-Rodriguez J, Chartrand L, Giannas B, Kapadia B, Meakins J, Rode H, Gordon J: Estimating mortality risk in preoperative patients using immunologic, nutritional, and acute-phase response variables. Ann Surg 1989;210:69-77.
34. Christou NV, Meakins JL, Gordon J, Yee J, Hassan-Zahraee M, Nohr CW, Shizgal HM, MacLean LD: The delayed hypersensitivity response and host resistance in surgical patients: 20 years later. Ann Surg 1995;222:534-538.
35. Schiffman K, Rinn K, Disis ML: Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients. Breast Cancer Res Treat 2002;74:17-23.
36. Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL: Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res 2000;6:1347-1350.
37. Pollock RE, Lotzova E, Stanford SD: Surgical stress impairs natural killer cell programming of tumor for lysis in patients with sarcomas and other solid tumors. Cancer 1992;70:2192-2202.
38. Mitchell MS, DeConti RC: Immunosuppression by 5-fluorouracil. Cancer 1970;26:884-889.
39. Philip PA: Gemcitabine and platinum combinations in pancreatic cancer. Cancer 2002;95:908-911.
40. Kurtz JE, Kohser F, Negrier S, Trillet-Lenoir V, Walter S, Limacher JM, Untereiner M, Kayitalire L, Jaeck D, Dufour P: Gemcitabine and protracted 5-FU for advanced pancreatic cancer: A phase II study. Hepatogastroenterology 2000;47:1450-1453.
41. Ota DM, Copeland EM 3rd, Corriere JN Jr, Dudrick SJ: The effects of nutrition and treatment of cancer on host immunocompetence. Surg Gynecol Obstet 1979;148:104-111.
42. Stefani S, Kerman R, Abbate J: Immune evaluation of lung cancer patients undergoing radiation therapy. Cancer 1976;37:2792-2796.